Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 double-blind study of S-268019-b for prevention of COVID-19
jRCT2031210269Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Aug 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of S-268019-b in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Incidence of adverse events, Incidence of adverse reactions and 5 more. Started Aug 2021; status: completed.
02
Drugs
S-268019-b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031210269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210269.